MarketCap
Facebook
X
TelegramQuarterly report 2022-Q2
added 08-19-2022
Calliditas Therapeutics AB (publ) Total Assets 2011-2026 | CALT
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Calliditas Therapeutics AB (publ)
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 1.46 B | 1.51 B | 845 M | 648 M | 62.3 M | 27.3 M | 28.1 M | - | - | - | - |
All numbers in SEK currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.51 B | 27.3 M | 654 M |
Quarterly Total Assets Calliditas Therapeutics AB (publ)
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 1.46 B | 1.34 B | 1.46 B | - | 1.19 B | 1.34 B | 1.46 B | - | 1.49 B | - | 845 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in SEK currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.49 B | 845 M | 1.32 B |
Total Assets of other stocks in the Drug manufacturers industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AcelRx Pharmaceuticals
ACRX
|
29.7 M | - | 7.5 % | $ 6.35 M |  USA |
 |
Alimera Sciences
ALIM
|
154 M | - | - | $ 142 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
431 M | - | - | $ 754 M | USA |
 |
Agile Therapeutics
AGRX
|
10.3 M | - | 10.11 % | $ 58.2 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
10.9 M | - | 0.86 % | $ 117 M | USA |
 |
Athenex
ATNX
|
204 M | - | -23.39 % | $ 1.76 M | USA |
 |
Aurora Cannabis
ACB
|
853 M | $ 3.42 | 3.01 % | $ 86.3 M |  Canada |
 |
Eagle Pharmaceuticals
EGRX
|
406 M | - | -39.89 % | $ 27.7 M | USA |
 |
Evoke Pharma
EVOK
|
7.07 M | - | - | $ 36.6 M | USA |
 |
Catalent
CTLT
|
9.75 B | - | - | $ 11.5 B | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
164 M | - | - | $ 2.06 B |  France |
 |
Cronos Group
CRON
|
1.93 B | $ 2.62 | 1.55 % | $ 1.39 B | Canada |
 |
DURECT Corporation
DRRX
|
45.2 M | - | - | $ 50.1 M | USA |
 |
Emergent BioSolutions
EBS
|
1.82 B | $ 8.21 | 2.43 % | $ 420 M | USA |
 |
Endo International plc
ENDP
|
5.14 B | - | - | $ 28.9 M |  Irlanda |
 |
Sundial Growers
SNDL
|
1.34 B | $ 1.36 | -0.73 % | $ 3.37 M | Canada |
 |
HEXO Corp.
HEXO
|
681 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Harrow Health
HROW
|
399 M | $ 36.35 | 3.27 % | $ 1.34 B | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
75.6 M | $ 3.35 | 7.03 % | $ 47.1 M | USA |
 |
Bausch Health Companies
BHC
|
27.4 B | $ 5.08 | 1.8 % | $ 1.85 B | Canada |
 |
PLx Pharma
PLXP
|
76.6 M | - | -27.8 % | $ 2.56 M | USA |
 |
Evolus
EOLS
|
226 M | $ 4.37 | -1.35 % | $ 282 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
289 M | - | - | $ 193 M | Canada |
 |
OptiNose
OPTN
|
108 M | - | - | $ 1.08 B | USA |
 |
Pacira BioSciences
PCRX
|
1.55 B | $ 23.49 | 1.25 % | $ 1.09 B | USA |
 |
PetIQ
PETQ
|
868 M | - | 1.64 % | $ 400 M | USA |
 |
Perrigo Company plc
PRGO
|
8.54 B | $ 9.69 | 0.52 % | $ 1.34 B | USA |
 |
ProPhase Labs
PRPH
|
87.6 M | - | - | $ 5.07 M | USA |
 |
Radius Health
RDUS
|
182 M | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
153 M | - | -4.76 % | $ 65.3 M | USA |
 |
Relmada Therapeutics
RLMD
|
94 M | $ 6.66 | 9.18 % | $ 263 M | USA |
 |
OrganiGram Holdings
OGI
|
408 M | $ 1.38 | 2.99 % | $ 402 M | Canada |
 |
Rockwell Medical
RMTI
|
52.2 M | $ 1.04 | 0.97 % | $ 24.3 M | USA |
 |
SCYNEXIS
SCYX
|
59 M | $ 0.88 | -2.13 % | $ 43.9 M | USA |
 |
Jupiter Wellness
JUPW
|
7.34 M | - | - | $ 33.6 M | USA |
 |
Solid Biosciences
SLDB
|
233 M | $ 7.23 | 8.23 % | $ 633 M | USA |
 |
China Pharma Holdings
CPHI
|
14.9 M | $ 0.6 | 2.41 % | $ 10.5 M |  China |
 |
Sonoma Pharmaceuticals
SNOA
|
13.7 M | $ 2.28 | -2.56 % | $ 2.83 M | USA |
 |
Assertio Holdings
ASRT
|
267 M | $ 18.57 | 12.48 % | $ 119 M | USA |
 |
Lannett Company
LCI
|
484 M | - | 1.15 % | $ 7.11 M | USA |
 |
Tilray
TLRY
|
4.31 B | $ 6.94 | 4.2 % | $ 4.29 B | Canada |
 |
Organogenesis Holdings
ORGO
|
498 M | $ 2.44 | 1.24 % | $ 321 M | USA |
 |
Canopy Growth Corporation
CGC
|
918 M | $ 0.97 | 1.5 % | $ 104 M | Canada |
 |
TherapeuticsMD
TXMD
|
43.3 M | $ 2.29 | - | $ 23.9 M | USA |
 |
Veru
VERU
|
60.4 M | $ 2.29 | - | $ 309 M | USA |
 |
Viatris
VTRS
|
50 B | $ 13.5 | 1.05 % | $ 16.2 B | USA |
 |
cbdMD
YCBD
|
10.6 M | $ 0.81 | 4.7 % | $ 3.49 M | USA |
 |
Tricida
TCDA
|
169 M | - | - | $ 3.25 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
55.5 M | - | - | $ 55.5 M | USA |